Gilead Sciences, Inc. (GILD)
| Market Cap | 157.63B |
| Revenue (ttm) | 29.09B |
| Net Income (ttm) | 8.11B |
| Shares Out | 1.24B |
| EPS (ttm) | 6.42 |
| PE Ratio | 19.73 |
| Forward PE | 14.98 |
| Dividend | $3.16 (2.49%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 5,572,524 |
| Open | 125.34 |
| Previous Close | 124.99 |
| Day's Range | 125.07 - 127.69 |
| 52-Week Range | 88.07 - 128.70 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 122.67 (-3.45%) |
| Earnings Date | Oct 30, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for GILD stock is "Buy." The 12-month stock price target is $122.67, which is a decrease of -3.45% from the latest price.
News
Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength
Gilead Sciences, Inc. continues to outperform, driven by its dominant HIV division and strong Q3 results that surpassed analyst expectations. GILD's HIV portfolio, led by Biktarvy and new launch Yeztu...
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million S...
Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. ( GILD) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Am...
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead's twice-yearly injectable HIV-1 c...
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
Gilead Sciences Inc. (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial.
Can Gilead Stock Outrun Regeneron In The Next Rally?
Regeneron Pharmaceuticals stock increased by 19% over the past month driven by strong third-quarter earnings and robust sales of its flagship drugs, Dupixent (for eczema and other inflammatory conditi...
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment resp...
Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. ( GILD) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Presentation Unknown Analyst Good mo...
AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit
LOS ANGELES--(BUSINESS WIRE)--As the pharmaceutical industry gathers for the Global Pharma & Biotech Summit in London this week, AIDS Healthcare Foundation (AHF) is launching a mobile billboard that w...
Gilead's breast cancer drug fails to meet main goal of late-stage study
Gilead Sciences said on Friday its breast cancer drug Trodelvy failed to meet the main goal of a late-stage study.
Gilead Provides Update on Phase 3 ASCENT-07 Study
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a fir...
Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living wi...
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Con...
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of He...
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (...
Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript
Gilead Sciences, Inc. ( GILD) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury and Investor Relations Daniel O'Day - Chairman &...
Gilead posts higher profit as HIV sales rise, helped by prevention drugs
Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit above Wall Stree...
Gilead Sciences Announces Third Quarter 2025 Financial Results
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. “We continue to deliver on Gilead's robust portfoli...
Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes
WASHINGTON--(BUSINESS WIRE)--Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes.
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
What To Expect From Gilead In Q3 2025
Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On...
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new research that reinforces its commitment to advancing innovation for people living with liver disease at The ...